Evidence map›Paper›PMID 40230861›Full record

ArticleFrontiers in immunology2025

Impact of single nucleotide polymorphisms of immunomodulatory factors on treatment response and prognosis in acute myeloid leukemia.

Mingying Li, Tao Sun, Mengyuan Chang, Tingting Liu, Lei Feng, Di Zhang, Yuyan Wu, Yuechan Ma, Huixian Ma, Guangqiang Meng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mingying Li *Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Tao Sun *Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Mengyuan ChangDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Tingting LiuDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Lei FengDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Di ZhangDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Yuyan WuDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Yuechan MaDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Huixian MaLaboratory of Cryomedicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Guangqiang MengDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Chunyan JiDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Jingjing YeDepartment of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute myeloid leukemia (AML) is a hematologic malignancy characterized by poor overall survival (OS). The impaired function, altered phenotype, and abnormal distribution of T cells create an immunosuppressive microenvironment in AML, affecting the efficacy of chemotherapy. Studies have shown that differentiated monocyte-like AML cells can express various immunomodulatory factors, resulting in T cell phenotypic changes and the development of an immunosuppressive AML microenvironment. Methods: Seven single nucleotide polymorphisms (SNPs) of four immunomodulatory factors-HMOX1, TXNIP, TNSF10/TRAIL, and TNFAIP2-were selected and analyzed in 255 non-M3 AML patients and 316 healthy controls. SNP genotyping was conducted using the MassARRAY platform. Furthermore, we analyzed the relationship between AML susceptibility, bone marrow (BM) blast percentage, clinical characteristics, treatment response, and prognosis with the selected SNPs. Results: The study indicated that HMOX1 rs2071746 and TNFAIP2 rs1132339 are associated with BM blasts at the diagnosis of AML patients. TXNIP rs7211 is associated with sensitivity to cytarabine- and anthracycline-induced chemotherapy in AML, while TXNIP rs9245 is associated with AML relapse. Moreover, TRAIL/TNFSF10 rs12488654 is associated with the overall survival of AML patients, and the AA genotype of TRAIL/TNFSF10 rs12488654 may be an independent favorable factor for AML prognosis. Conclusions: Our results on the association between AML and SNPs in HMOX1, TXNIP, TNSF10/TRAIL, and TNFAIP2 genes provide an important reference for predicting the treatment response and prognosis of AML patients.

Indexed as

Carrier ProteinsLeukemia, Myeloid, AcutePolymorphism, Single NucleotideAdolescentAdultAgedFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedPrognosisTreatment OutcomeYoung AdultCarrier ProteinsTXNIP protein, humanAMLimmunoregulatory factorsprognosisSNPstreatment response

Identifiers

PMID40230861
PMCPMC11994645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.